Article Details
Retrieved on: 2021-03-25 11:26:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Ibrance, which received regulatory approval in the U.S. as a first-line treatment in 2017, generated $5.4 billion in revenue in 2020. Pfizer's stock is up ...
Article found on: www.marketwatch.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here